Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma

Paramita, Dewi Kartikawati; Fachiroh, Jajah; Haryana, Sofia Mubarika; Middeldorp, Jaap M.

doi:10.1016/j.jcv.2008.03.006

Cited by 17 publications

(12 citation statements)

References 39 publications

(73 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…47 An association between EBV and NPC was shown by markedly higher positivity for IgA anti-EBNA-1 antibodies in our PM/DM patients with NPC compared to those without NPC and HC, which is consistent with previously reported finding. [22][23][24][25]48,49 Although immunosuppression may reactivate latent EBV infection 46 and then predispose myositis patients to develop NPC, we showed no significant differences in the mean doses of daily corticosteroids or the proportion of used immunosuppressant between PM/DM patients with and without NPC. Among those individuals with detectable EBV DNA, we found that myositis patients with NPC had a ∼837-fold increase in circulating EBV viral loads compared with HC, a ∼999-fold increase compared with PM/DM without malignancy, and a ∼456-fold increase compared with SLE patients.…”

Section: Discussionmentioning

confidence: 93%

Polymyositis/dermatomyositis and nasopharyngeal carcinoma: The Epstein–Barr virus connection?

Chen

Lan

et al. 2010

Journal of Clinical Virology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 93%

Polymyositis/dermatomyositis and nasopharyngeal carcinoma: The Epstein–Barr virus connection?

Chen

Lan

et al. 2010

Journal of Clinical Virology

View full text Add to dashboard Cite

“…EBV antibody profiling by immunoblot for serological confirmation and detection of acute, chronic or aberrant EBV infection has proven informative and has reached commercial platforms (Bauer 2001;Fachiroh et al 2004;de Sanjosé et al 2007;Paramita et al 2008, de Ory et al 2014.…”

Section: Molecular Details Of Anti-ebv Antibody Responses During and mentioning

confidence: 99%

Epstein-Barr Virus-Specific Humoral Immune Responses in Health and Disease

Middeldorp

2015

Current Topics in Microbiology and Immunology

Self Cite

View full text Add to dashboard Cite

Epstein-Barr virus (EBV) is widely distributed in the world and associated with a still increasing number of acute, chronic, malignant and autoimmune disease syndromes. Humoral immune responses to EBV have been studied for diagnostic, pathogenic and protective (vaccine) purposes. These studies use a range of methodologies, from cell-based immunofluorescence testing to antibody-diversity analysis using immunoblot and epitope analysis using recombinant or synthetic peptide-scanning. First, the individual EBV antigen complexes (VCA , MA, EA(D), EA(R) and EBNA) are defined at cellular and molecular levels, providing a historic overview. The characteristic antibody responses to these complexes in health and disease are described, and differences are highlighted by clinical examples. Options for EBV vaccination are briefly addressed. For a selected number of immunodominant proteins, in particular EBNA1, the interaction with human antibodies is further detailed at the epitope level, revealing interesting insights for structure, function and immunological aspects, not considered previously. Humoral immune responses against EBV-encoded tumour antigens LMP1, LMP2 and BARF1 are addressed, which provide novel options for targeted immunotherapy. Finally, some considerations on EBV-linked autoimmune diseases are given, and mechanisms of antigen mimicry are briefly discussed. Further analysis of humoral immune responses against EBV in health and disease in carefully selected patient cohorts will open new options for understanding pathogenesis of individual EBV-linked diseases and developing targeted diagnostic and therapeutic approaches.

show abstract

“…In our study, we detected the EBV-related proteins with a western blot test kit, determined the scores of each test strip according to the color depth (Paramita et al, 2008), and compared scores of the VCA-IgG, EAIgG, and EBNA1-IgG antibodies in four subject groups with specific VCA-IgA/EA-IgA profiles. The results demonstrate that EA-D p45-IgG is a potential biomarker for NPC diagnosis.…”

Section: Introductionmentioning

confidence: 99%